Roche Holdings AG DIV RT (RHHVF)$425.05
Market Cap: 263.81 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Roche Holdings AG DIV RT (RHHVF).
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
N/A
ROIC, N/A FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
N/A
Debt/equity, N/A current ratio
Superinvestors
0
No tracked positions
Strengths to research
No strong positive screening signals were detected from the checked-in dataset.
Watchouts
- Full metrics are not available yet for this ticker.
Annual data: 0 periods
Quarterly data: 3 periods
Stock snapshot: May 24, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for RHHVF.
Grade F
0
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| RHHVF Target | Roche Holdings AG DIV RT | $263.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RHHBY | Roche Holding AG ADR | $265.2B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| NVO | Novo Nordisk A S | $305.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| NVS | Novartis AG | $223.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| MRK | Merck & Co. | $208.5B | 16.8x | 15.7x | 34.7% | 9.4% | 19.0% | N/A | N/A | N/A |
| ABBV | AbbVie Inc. | $346.8B | 91.4x | 22.8x | 6.9% | 6.0% | 29.1% | N/A | 3.7x | N/A |
| JNJ | Johnson & Johnson | $372.9B | 21.2x | 20.0x | 21.8% | 2.7% | 20.9% | 67.9% | N/A | N/A |
| AMGN | Amgen | $150.6B | 23.8x | 24.2x | 12.2% | 7.6% | 22.0% | N/A | 3.2x | N/A |
| PFE | Pfizer Inc. | $135.4B | 19.0x | 14.8x | 9.0% | 8.5% | 14.5% | N/A | N/A | N/A |
Financial Charts
No financial data available for RHHVF (annual).